Profund Advisors LLC Has $1.43 Million Stock Holdings in Medtronic PLC $MDT

Profund Advisors LLC lowered its holdings in shares of Medtronic PLC (NYSE:MDT) by 6.6% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,378 shares of the medical technology company’s stock after selling 1,163 shares during the period. Profund Advisors LLC’s holdings in Medtronic were worth $1,428,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of MDT. 1248 Management LLC acquired a new position in Medtronic during the first quarter worth about $26,000. Twin Tree Management LP acquired a new position in Medtronic during the 1st quarter worth approximately $29,000. Activest Wealth Management lifted its stake in Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after purchasing an additional 322 shares during the last quarter. Hughes Financial Services LLC acquired a new stake in Medtronic in the first quarter valued at approximately $32,000. Finally, Investment Management Corp VA ADV boosted its position in Medtronic by 144.2% in the first quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock valued at $36,000 after buying an additional 238 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William R. Jellison bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were acquired at an average cost of $92.37 per share, with a total value of $230,925.00. Following the purchase, the director directly owned 5,000 shares of the company’s stock, valued at $461,850. This trade represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.26% of the company’s stock.

Medtronic Trading Up 0.5%

Shares of MDT stock opened at $92.69 on Tuesday. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $99.37. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The stock has a market cap of $118.89 billion, a price-to-earnings ratio of 25.53, a PEG ratio of 2.42 and a beta of 0.77. The stock has a 50-day moving average of $94.20 and a 200-day moving average of $90.11.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were issued a $0.71 dividend. The ex-dividend date was Friday, September 26th. This represents a $2.84 annualized dividend and a yield of 3.1%. Medtronic’s payout ratio is presently 78.24%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Robert W. Baird increased their price target on Medtronic from $94.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, August 20th. Morgan Stanley reiterated an “overweight” rating and issued a $107.00 target price (up from $98.00) on shares of Medtronic in a research report on Tuesday, July 15th. Daiwa Capital Markets lifted their price target on Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, September 12th. The Goldman Sachs Group lowered their price objective on Medtronic from $82.00 to $81.00 and set a “sell” rating for the company in a research note on Wednesday, October 1st. Finally, Argus raised their price objective on shares of Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $102.82.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.